Eqis Capital Management, Inc. Crispr Therapeutics Ag Transaction History
Eqis Capital Management, Inc.
- $1.15 Billion
- Q4 2024
A detailed history of Eqis Capital Management, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Eqis Capital Management, Inc. holds 10,017 shares of CRSP stock, worth $435,639. This represents 0.03% of its overall portfolio holdings.
Number of Shares
10,017
Previous 8,161
22.74%
Holding current value
$435,639
Previous $383,000
2.87%
% of portfolio
0.03%
Previous 0.03%
Shares
16 transactions
Others Institutions Holding CRSP
# of Institutions
488Shares Held
60.3MCall Options Held
1.26MPut Options Held
1.81M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$390 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$380 Million0.07% of portfolio
-
State Street Corp Boston, MA2.99MShares$130 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$121 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.75MShares$119 Million1.21% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.39B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....